iNtRON Biotechnology

At a glance

iNtRON Biotechnology filed 38 disclosures in the last 12 months, including 9 insider, 5 5% holder, 5 buyback and 1 issuance. The most recent key filing was on Aug 27: A major holder's stake rose from 18.82% to 18.82% (share lending).

Revenue for 2025 was ₩5.7B, down 10.6% on 2024. It made an operating loss of ₩7.9B. Debt was 6% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.9B and operating loss of ₩3.8B.

The 2025 annual report lists 77 employees with an average tenure of 7.5 years and average pay of ₩64.3M, #930 of 2,191 listed companies by average pay. Its 4 directors and auditors were paid ₩221.7M each on average. It paid no cash dividend for 2025. 윤성준 and related parties held 17.35% at year end.

Of 4 recent 5%+ holder reports, 2 raised and 0 cut a stake; the largest stake reported was 18.82% on Aug 27.

From the 2025 annual report

Staff: 77 (45 men, 32 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩5B. Directors and auditors: 4, paid ₩886.6M in total.

No cash dividend was paid for 2025.

Largest shareholder

윤성준 holds 11.75%; with 3 related parties the group holds 17.35% of common shares at year end (from 15.67% at the start of the year).

Auditor: 신한회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports